Centre for Human Drug Research is a foundation established under Dutch law. Its articles of association determine that the foundation is governed by a two-tier board system: an Executive Board supervised by a non-executive Supervisory Board.
The Executive Board is responsible for designing and implementing the strategy and policies of the foundation. The tasks and responsibilities of the Executive Board are set out in the Executive Board Statute of CHDR in more detail. By Dutch law, members of the Executive Board are appointed by the Supervisory Board, and business decisions with a significant financial or organizational impact are subject to prior approval of the Supervisory Board.
The Executive Board is currently formed by:
- Koos Burggraaf, Chief Executive Officer
- Geert Jan Groeneveld, Chief Scientific Officer/Chief Medical Officer
The Executive Board is supported by a Management Team that is comprised of senior staff of the company. The members of the Management Team are collectively and individually responsible for the daily management (of a part) of the organization delegated to them by the Executive Board.
The Management Team is chaired by the Executive Board and current members are:
- Yvette Akkermans, HR Director
- Gabriel Jacobs, Research Director
- Bart van der Kroef, Technology Director
- Matthijs Moerland, Research Director
- Bart Mooy, Financial Director
- Margreet Rienstra, Compliance Director
- Robert Rissmann, Research Director
- Ard Vink, Clinical Operations Director
The Supervisory Board is charged with supervising the policy of the Executive Board and the general affairs of the foundation, and advising the Executive Board. Tasks and responsibilities are defined in the Regulations for the Supervisory Board. The Supervisory Board meets in principle 4 times per year.
The Supervisory Board has installed 3 committees:
- Audit committee: monitors CHDR’s financial reporting and control systems;
- Remuneration committee: reviews the performance of the Executive Board and draws up proposals for the remuneration of the Executive Board and Supervisory Board;
- Committee Quality and Scientific Integrity: reviews CHDRs measures and policies on quality and scientific integrity.
The tasks and responsibilities of each committee are set forth in separate regulations for each committee.
Certain decisions of the Management Board and the Supervisory Board are subject to a final advice or decision by the Employee Council. This is a legal requirement imposed by the Employee Council Law (Wet op de Ondernemingsraad) of the Netherlands.
In order to maintain a sound financial position CHDR has implemented the following:
- CHDR Treasury Regulations which provides principles and guidelines regarding cash flow management, financing and risk management
- CHDR Investment Statute (currently in draft) which provides guidelines that ensure that investment decisions are based on sound considerations and thorough research
Scientific Advisory Board
The Scientific Advisory Board (SAB) advises CHDR on the scientific quality of CHDR’s projects and on the general scientific strategy. In addition, the SAB serves an important role in the education and proficiency of CHDR's PhD-candidates, trainees and interns.
SAB members are nominated by CHDR's CEO and Research Directors. The SAB members are external members. The composition of the SAB is chosen to reflect the expertise necessary to cover the activities and specific interest of CHDR. The SAB consists of at least five external members, elected for their expertise in various areas of pharmacology and medicine.
The role of the SAB is set out in a standard operating procedure “Scientific Review”.
List of members of the SAB, can be found here.